このエントリーをはてなブックマークに追加
ID 60983
フルテキストURL
fulltext.pdf 1.31 MB
著者
Ejiri, Kentaro Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences ORCID publons researchmap
Miyoshi, Toru Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences ORCID Kaken ID publons
Kihara, Hajime Department of Internal Medicine, Kihara Cardiovascular Clinic
Hata, Yoshiki Department of Cardiology, Minamino Cardiovascular Hospital
Nagano, Toshihiko Department of Internal Medicine, Iwasa Hospital
Takaishi, Atsushi Department of Cardiology, Mitoyo General Hospital
Toda, Hironobu Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences
Nanba, Seiji Department of Cardiology, Okayama Rosai Hospital
Nakamura, Yoichi Department of Cardiovascular Medicine, Specified Clinic of Soyokaze Cardiovascular Medicine and Diabetes Care
Akagi, Satoshi Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences ORCID Kaken ID
Sakuragi, Satoru Department of Cardiovascular Medicine, Iwakuni Clinical Center
Minagawa, Taro Department of Internal Medicine, Minagawa Cardiovascular Clinic
Kawai, Yusuke Department of Cardiovascular Medicine, Okayama City Hospital
Nishii, Nobuhiro Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Kaken ID publons
Fuke, Soichiro Department of Cardiovascular Medicine, Japanese Red Cross Okayama Hospital
Yoshikawa, Masaki Department of Cardiology, Fukuyama City Hospital
Nakamura, Kazufumi Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Kaken ID publons researchmap
Ito, Hiroshi Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Kaken ID
抄録
Background
Effects of sodium‐glucose cotransporter 2 inhibitors on reducing hospitalization for heart failure have been reported in randomized controlled trials, but their effects on patients with heart failure with preserved ejection fraction (HFpEF) are unknown. This study aimed to evaluate the drug efficacy of luseogliflozin, a sodium‐glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus and HFpEF.
Methods and Results
We performed a multicenter, open‐label, randomized, controlled trial for comparing luseogliflozin 2.5 mg once daily with voglibose 0.2 mg 3 times daily in patients with type 2 diabetes mellitus suffering from HFpEF (left ventricular ejection fraction >45% and BNP [B‐type natriuretic peptide] concentrations ≥35 pg/mL) in a 1:1 randomization fashion. The primary outcome was the difference from baseline in BNP levels after 12 weeks of treatment between the 2 drugs. A total of 173 patients with diabetes mellitus and HFpEF were included. Of these, 83 patients were assigned to receive luseogliflozin and 82 to receive voglibose. There was no significant difference in the reduction in BNP concentrations after 12 weeks from baseline between the 2 groups. The ratio of the mean BNP value at week 12 to the baseline value was 0.79 in the luseogliflozin group and 0.87 in the voglibose group (percent change, −9.0% versus −1.9%; ratio of change with luseogliflozin versus voglibose, 0.93; 95% CI, 0.78–1.10; P=0.26).
Conclusion
In patients with type 2 diabetes mellitus and HFpEF, there is no significant difference in the degree of reduction in BNP concentrations after 12 weeks between luseogliflozin and voglibose.
キーワード
B-type natriuretic peptide
diabetes mellitus
heart failure
sodium-glucose cotransporter 2 inhibitor
発行日
2020-08-18
出版物タイトル
Journal of the American Heart association
9巻
16号
出版者
Wiley
開始ページ
e015103
ISSN
2047-9980
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2020 The Authors.
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1161/JAHA.119.015103
ライセンス
https://creativecommons.org/licenses/by-nc-nd/4.0/